Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676715 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00676715 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 220 participants.
The verdict
NCT00676715, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Interventions
- DRUG Placebo
- DRUG Avonex
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2008-07-17 |
| Est. Completion | 2023-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676715
The ClinicalTrials.gov registry entry for NCT00676715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00676715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676715 about?
NCT00676715 is a clinical study titled "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis". This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multi...
What is the current status of trial NCT00676715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2008-07-17. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT00676715?
The interventions under investigation include: Placebo (DRUG), Avonex (DRUG), Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT00676715?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.